109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
癌症精准纳米医学：创新、策略与转化挑战
Authors Wen F, Wang L, Li X, Zhao J, Xu T, Zhu J, Ma L, Wang X
Received 27 June 2025
Accepted for publication 29 September 2025
Published 10 October 2025 Volume 2025:18 Pages 1125—1148
DOI https://doi.org/10.2147/OTT.S550104
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Editor who approved publication: Dr John Maher
Fuxing Wen,1 Lishuang Wang,2 Xian Li,3 Jiajia Zhao,4 Tingting Xu,1 Jingkai Zhu,1 Lijuan Ma,1 Xiaodong Wang5
1Jilin City Hospital of Chemical Industry, Department of Gastroenterology, Jilin City, Jilin, 132022, People’s Republic of China; 2Jilin City Hospital of Chemical Industry, Department of Cardiology, Jilin City, Jilin, 132022, People’s Republic of China; 3Jilin City Hospital of Chemical Industry, Hematology Department, Jilin City, Jilin, 132022, People’s Republic of China; 4The Second Affiliated Hospital of Shaoyang University, Department of Gastroenterology, Shaoyang, Hunan, 422000, People’s Republic of China; 5The Second Hospital of Jilin University, Gastroenteric Medicine and Digestive Endoscopy Center, Changchun, Jilin, 130041, People’s Republic of China
Correspondence: Lishuang Wang, Jilin City Hospital of Chemical Industry, Department of Cardiology, Jilin City, Jilin, 132022, People’s Republic of China, Email 33627432@qq.com
Abstract: As nanotechnology advances rapidly, it has propelled nanomedicine into a revolutionary frontier for anticancer therapy. This review comprehensively analyzes the core principles, key innovations, and strategic approaches driving the development of targeted nanotherapeutics against tumors. We elucidate the distinctive properties of nanoscale drug delivery systems (eg, liposomes, polymeric nanoparticles, inorganic nanoparticles, and hybrid systems) and their capacity to be designed to surmount the constraints of traditional cancer treatments by potentially augmenting drug specificity, bioavailability, and minimizing systemic toxicity, with some nanocarriers (eg, liposomal doxorubicin) already approved for clinical use. With a focus on both the enhanced permeability and retention (EPR) effect-mediated passive targeting and ligand-based active targeting mechanisms employing peptides, aptamers, and antibodies, we investigate how these nanocarriers are engineered for efficient tumor-targeted drug delivery. The review further delves into the understanding of nano-bio interactions (eg, size-dependent cellular uptake) and their interplay with cancer biology. We discuss how this knowledge, alongside the rational design of stimuli-responsive and multifunctional “smart” nanoplatforms, informs the development of more precise and effective therapeutic strategies. Finally, we address the ongoing challenges in clinical translation, such as patient heterogeneity and physiological barriers, and emphasize that comprehending these aspects is pivotal for guiding future translational research towards the realization of truly patient-centric nanomedicines.
Keywords: targeted nanomedicine, cancer therapy, nanocarriers, drug delivery systems, active and passive targeting
1Jilin City Hospital of Chemical Industry, Department of Gastroenterology, Jilin City, Jilin, 132022, People’s Republic of China; 2Jilin City Hospital of Chemical Industry, Department of Cardiology, Jilin City, Jilin, 132022, People’s Republic of China; 3Jilin City Hospital of Chemical Industry, Hematology Department, Jilin City, Jilin, 132022, People’s Republic of China; 4The Second Affiliated Hospital of Shaoyang University, Department of Gastroenterology, Shaoyang, Hunan, 422000, People’s Republic of China; 5The Second Hospital of Jilin University, Gastroenteric Medicine and Digestive Endoscopy Center, Changchun, Jilin, 130041, People’s Republic of China
Correspondence: Lishuang Wang, Jilin City Hospital of Chemical Industry, Department of Cardiology, Jilin City, Jilin, 132022, People’s Republic of China, Email 33627432@qq.com
Abstract: As nanotechnology advances rapidly, it has propelled nanomedicine into a revolutionary frontier for anticancer therapy. This review comprehensively analyzes the core principles, key innovations, and strategic approaches driving the development of targeted nanotherapeutics against tumors. We elucidate the distinctive properties of nanoscale drug delivery systems (eg, liposomes, polymeric nanoparticles, inorganic nanoparticles, and hybrid systems) and their capacity to be designed to surmount the constraints of traditional cancer treatments by potentially augmenting drug specificity, bioavailability, and minimizing systemic toxicity, with some nanocarriers (eg, liposomal doxorubicin) already approved for clinical use. With a focus on both the enhanced permeability and retention (EPR) effect-mediated passive targeting and ligand-based active targeting mechanisms employing peptides, aptamers, and antibodies, we investigate how these nanocarriers are engineered for efficient tumor-targeted drug delivery. The review further delves into the understanding of nano-bio interactions (eg, size-dependent cellular uptake) and their interplay with cancer biology. We discuss how this knowledge, alongside the rational design of stimuli-responsive and multifunctional “smart” nanoplatforms, informs the development of more precise and effective therapeutic strategies. Finally, we address the ongoing challenges in clinical translation, such as patient heterogeneity and physiological barriers, and emphasize that comprehending these aspects is pivotal for guiding future translational research towards the realization of truly patient-centric nanomedicines.
Keywords: targeted nanomedicine, cancer therapy, nanocarriers, drug delivery systems, active and passive targeting